expect barrag clinic data begin
tuesday biolinerx report net loss higher estim
larg due higher anticip expens associ initi
phase genesi trial believ data-rich year new
clinic result expect least four on-going trial valuat
biolinerx center potenti stem cell mobil anticip
result lead-in cohort genesi autolog transplant well top line
phase result allogen transplant result chase
oncolog readout includ top line phase data pancreat cancer
interim data variou cohort roch morpheu phase adapt
platform reiter outperform pt
offer multipl opportun compani demonstr clinic
proof-of-concept cancer therapi potenti significantli
expand market opportun collabor merck roch
biolinerx investig multipl early-stag studi across rang
solid liquid tumor new cohort lung cancer patient slate begin
last month compani present biomark data combat studi
plu pembrolizumab pancreat cancer show lead-in dose
elicit increas t-cell infiltr tumor biopsi
expect top-lin result combat given challeng natur
indic would view object clinic respons highli encourag
phase genesi trial initi decemb trial enrol multipl
myeloma patient undergo autolog stem cell transplant compar stem
cell mobil g-csf g-csf alon lead-in cohort
patient use evalu safeti efficaci slightli higher dose
mg/kg use prior studi
second asset slate enter clinic synthet
alpha-g glycolipid design co-opt pre-exist antibodi alpha-g
effect tag cancer cell immune-medi destruct januari
melanoma
biolinerx end cash equival estim
could sustain oper end expect compani increas
 expenditur enter clinic project
quarterli burn base discuss manag revis
clinical-stag bio-
pharmaceut compani focus
hematolog malign
analyst certif import disclosur see disclosur appendix
rate blrx outperform pt
base risk-adjust revenu ep multipl analysi
valuat base commerci potenti
auto-hsct mobil believ result phase
genesi trial could spur major transplant physician
choos mozobil combin g-csf drug
approv upsid thesi includ use allo-
hsct aml solid tumor compani boast catalyst-
rich deep oncolog pipelin attract collabor
novarti merck genentech
genesi readout patient multipl myeloma mm
undergo auto-hsct fda approv
success bridg studi expand label auto-hsct non-
risk-adjust peak market stem cell
mobil us eu market
potenti result lead genesi cohort
potenti top-lin result phase studi use
potenti pancreat cancer phase
potenti interim readout phase morpheu studi
solid tumor
potenti interim readout on-going blast studi
better expect uptak mobil auto-hsct
expans allo-hsct
clinic success blast and/or battl trial
potenti lead approv aml
clinic success use solid tumor
clinic success earli stage program
clinical/regulatori failur auto-hsct uptak
auto-hsct
compani pursu label expans nhl
limit on-label use patient mm
price target per share deriv discount project revenu ep risk-
adjust target multipl line histor multipl profit biotech compani given current stage
develop stem cell mobil project potenti launch
risk includ clinic regulatori financ competit market price pressur
note view blrx stock trade specul appropri risk-toler investor
stem cell mobil
potenti result lead-in genesi cohort
potenti top-line result investig sponsor trial allogen stem cell
solid tumor aml
potenti interim result studi pancreat cancer
initi phase cohort atezolizumab combin nsclc
potenti interim readout blast studi aml consolid
potenti top-line result trial
potenti interim readout phase studi atezolizumab solid tumor
solid tumor
potenti initi phase monotherapi studi solid tumor
compani present oppenheim co
sec file oppenheim co research
figur thousand except per share stem cell mobil expens good sold research develop sale market gener administr oper incom incom loss incom incom incom loss attribut common per share share outstand co inc mark breidenbach blrx outperform
sec file oppenheim co research
figur thousand except per share cash short-term bank prepaid current long-term prepaid long-term properti equip intang asset non-curr current matur long-term bank account payabl accrual current long-term bank loan net current non-curr equiti ordinari share capit comprehens accumul stockhold liabil stockhold co inc mark breidenbach biolinerx
stock price compani mention report mid-day
